Kramer M Gabriela, Masner Martín, Ferreira Fernando A, Hoffman Robert M
Department of Biotechnology, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Laboratory of Carbohydrates and Glycoconjugates, Department of Organic Chemistry, Facultad de Química, Universidad de la República, Montevideo, Uruguay.
Front Microbiol. 2018 Jan 23;9:16. doi: 10.3389/fmicb.2018.00016. eCollection 2018.
Spontaneous tumors regression has been associated with microbial infection for 100s of years and inspired the use of bacteria for anticancer therapy. Dr. William B. Coley (1862-1936), a bone- sarcoma surgeon, was a pioneer in treating his patients with both live bacterial-based and mixture of heat-killed bacteria known as "Coley's toxins." Unfortunately, Coley was forced to stop his work which interrupted this field for about half a century. Currently, several species of bacteria are being developed against cancer. The bacterial species, their genetic background and their infectious behavior within the tumor microenvironment are thought to be relevant factors in determining their anti-tumor effectiveness . In this perspective article we will update the most promising results achieved using bacterial therapy (alone or combined with other strategies) in clinically-relevant animal models of cancer and critically discuss the impact of the bacterial variants, route of administration and mechanisms of bacteria-cancer-cell interaction. We will also discuss strategies to apply this information using modern mouse models, molecular biology, genetics and imaging for future bacterial therapy of cancer patients.
数百年来,肿瘤的自发消退一直与微生物感染有关,并激发了利用细菌进行抗癌治疗的想法。骨肉瘤外科医生威廉·B·科利博士(1862 - 1936)是用活细菌和热灭活细菌混合物(即“科利毒素”)治疗患者的先驱。不幸的是,科利被迫停止他的工作,这使得该领域中断了大约半个世纪。目前,正在研发几种抗癌细菌。细菌种类、它们的遗传背景以及它们在肿瘤微环境中的感染行为被认为是决定其抗肿瘤效果的相关因素。在这篇观点文章中,我们将更新在临床相关癌症动物模型中使用细菌疗法(单独或与其他策略联合使用)所取得的最有前景的结果,并批判性地讨论细菌变体、给药途径以及细菌与癌细胞相互作用机制的影响。我们还将讨论利用现代小鼠模型、分子生物学、遗传学和成像技术应用这些信息以用于未来癌症患者细菌治疗的策略。